Although most Ets transcription factors have been characterized as transcriptional activators, some of them display repressor activity. Here we characterize an Etsfamily member, the very specifically expressed human Fifth Ewing Variant (FEV), as a transcriptional repressor. We show that among a broad range of human cell lines, only Dami megakaryocytic cells express FEV. This nuclear protein binds to Ets-binding sites, such as that of the human ICAM-1 promoter. We used this promoter to demonstrate that FEV can repress both basal transcription and, even more strongly, ectopically Ets-activated transcription. We identified two domains responsible for FEV-mediated repression: the ETS domain, responsible for passive repression, and the carboxy-terminal alaninerich domain, involved in active repression. In the Ets-independent LEXA system also, FEV acts as a transcriptional repressor via its alanine-rich carboxyterminal domain. The mechanism by which FEV actively represses transcription is currently unknown, since FEVtriggered repression is not reversed by the histone deacetylase inhibitor trichostatin A. We also showed that long-term overexpression of FEV proteins containing the alanine-rich domain prevents cell clones from growing, whereas clones expressing a truncated FEV protein lacking this domain develop like control cells. This confirms the importance of this domain in FEV-triggered repression.
Introduction
Transcriptional repression has emerged over the last decade as a key mechanism in the regulation of eukaryotic gene expression, balancing, or blocking transcription of a given gene in a specific context. Repressor proteins regulate their target genes through direct or indirect binding to DNA in regulatory regions of the gene of interest (Courey and Jia, 2001) . They can repress transcription by a variety of mechanisms, such as displacing an activator from the DNA or blocking the activation domain of a transcriptional activator (Bird and Wolffe, 1999) . They can also interact directly with the basal transcription machinery or affect chromatin structure and DNA accessibility.
A few ETS-domain transcription factors have been identified as repressors (for a review, see Mavrothalassitis and Ghysdael, 2000) . The ets genes encode a family of over 40 proteins identified in a wide range of organisms, from sponges to humans (for a review, see Sharrocks, 2001 ). The signature of this family of transcription factors is the winged 85-amino-acid helixturn-helix ETS DNA-binding domain (Karim et al., 1990) , which binds to sites containing a central 5 0 -GGAA/T-3 0 motif. In addition to displaying high amino-acid conservation in the ETS domain, Ets-family factors can be placed in subclasses on the basis of conservation of other domains (for a review, see Sharrocks, 2001) . Although some Ets factors, previously characterized as transcriptional activators, have also been shown to act as repressors in specific contexts (Sieweke et al., 1996; Li et al., 2000; Xing et al., 2000) , a few of them act exclusively as transcriptional repressors. This is the case of Erf, Net, Net-b, Net-c, Tel, Tel-2, and Yan (O'Neill et al., 1994; Sgouras et al., 1995; Maira et al., 1996; Chakrabarti and Nucifora, 1999; Lopez et al., 1999) .
The fev gene (for the Fifth Ewing Variant (FEV)) was recently cloned as the result of a chromosomal translocation in a human Ewing tumor in a child: part of this gene was fused to part of the sequence encoding the RNA-binding protein EWS (Peter et al., 1997) . Human FEV is encoded by three exons located on chromosome 2. It displays a centrally located ETS DNA-binding domain. Since its ETS domain shares high sequence identity with Fli-1 and Erg-1, FEV appears to belong to the Erg group (Peter et al., 1997) .
Although many ets genes are expressed at all times in all tissues (Graves and Petersen, 1998; de Launoit et al., 2000; Maroulakou and Bowe, 2000; Sharrocks, 2001 ), fev expression is restricted to the prostate and small intestine of adults (Peter et al., 1997) . No human fetal tissue has been found to express fev. Although data concerning the function of FEV are scant, this factor was initially proposed as a transcriptional repressor because the 112-residue span forming its Cterminus is rich in alanine (Peter et al., 1997) , a feature observed in various transcriptional repressors (Yeung et al., 1994) .
In the present work, we have tested numerous human cell lines for the expression of the fev gene. Among them, only Dami megakaryocytic cells tested positive. In addition, we have shown that this nuclear protein can repress Ets-dependent reporter genes, and that both the ETS domain and the alanine-rich C-terminal domain are involved in this phenomenon. Stable ectopic overexpression of FEV in cells that do not normally express this gene prevents the cells from growing. This suggests that FEV-mediated transcriptional repression might act on several crucial cell mechanisms.
Results

Expression of FEV in human cell lines
Previous work has shown that FEV is expressed exclusively in two human adult tissues, the prostate and the small intestine (Peter et al., 1997) . To obtain a cell model expressing this factor, we screened a large series of human cell lines for FEV mRNA. As none of the probes used in Northern blot analyses enabled us to detect an FEV-specific signal (data not shown), we resorted to RT -PCR. After reverse transcription and 40 cycles of PCR amplification, neither the LnCaP, Du-145, or PC3 prostatic cancer cell lines nor the HCT-15 or Lovo human intestinal cancer cell lines were found to express the fev gene (Figure 1 ). We did show, however, that the human prostate produces FEV mRNA The PEI Exgen 500 procedure was used to transfect the cells with the pSG5-FEV plasmid. At 24 h after transfection, the cells were fixed and incubated with 1 : 50 diluted specific goat anti-FEV C18 antibody (Santa Cruz) followed by incubation with a fluorescein-conjugated donkey anti-goat IgG antibody. (b) DNA binding of in vitro synthesized human FEV to the ICAM-1 promoter. An EMSA of bacterially produced GST and FEV fused to GST (GST-FEV) was performed with doublestranded end-labeled oligonucleotide primers corresponding to the À175 to À145 region of the human ICAM-1 promoter. The FEV protein-DNA complex (arrow) was separated from the free probe (*) on a nondenaturing 6% polyacrylamide gel. S indicates the supershifted band when GST-FEV was incubated with a specific anti-FEV N19 (Santa Cruz) goat antibody (Anti-FEV). (c) EMSA was performed as in (b), in the presence of a 400-fold excess of unlabeled competitor oligonucleotides (ICAM or E74) containing either wild-type (wt) or mutant (mut) Ets-binding sites MDA-MB-231 mammary adenocarcinoma cell lines, the JAR, JEG-3, and Bewo placental adenocarcinoma cell lines, the HeLa cervical carcinoma cell line, the HEPG2 hepatocarcinoma cell line, the A427 lung carcinoma cell line, the HEK-293 embryonic kidney carcinoma cell line, and the MOLT-4 and Jurkat lymphoblastic leukemia cell lines (data not shown).
Nuclear localization of FEV and interaction with Ets-responsive elements FEV contains an ETS domain, signature of the Ets family. The nuclear localization of most Ets proteins is because of this domain . We performed immunofluorescence experiments with an anti-FEV antibody to confirm the subcellular localization of FEV. Unfortunately, we failed to detect any specific labeling of Dami cells by this approach. We thus used pSG5-FEV-transfected COS-7 cells to determine the subcellular localization of FEV. As shown in Figure 2a , FEV was found exclusively in the nucleus.
To test the DNA-binding properties of FEV, we overproduced full-length FEV fused to GST in bacteria. The resulting chimeric protein (approximately 50 kDa) was used in electrophoretic mobility shift analyses. To test the ability of FEV to bind specifically to DNA we used several oligonucleotide probes, each containing a functional Ets-binding site. We report here the data obtained with the functional Ets site of the human ICAM-1 promoter (de Launoit et al., 1998) . Although GST alone did not bind to the 32 P-labeled doublestranded ICAM-1 oligonucleotide, GST-FEV did bind to it, as illustrated by a major specific shift (Figure 2b ). We further showed that probe-bound GST-FEV is recognized by a specific anti-FEV antibody, as indicated by its retardation on the gel (Figure 2b ). The probe was displaced from the complex in the presence of a 400-fold excess of the corresponding unlabeled ICAM-1 competitor oligonucleotide (ICAM wt, Figure 2c ). In contrast, an excess of Ets-mutated ICAM-1 oligonucleotide (ICAM mut) did not displace the probe. We also tested competition with a 400-fold excess of unlabeled wildtype and Ets-mutated E74 oligonucleotide (Baert et al., 2002) . Only the wild-type E74 oligonucleotide was able to displace the radiolabeled ICAM-1 probe from the FEV-probe complex (Figure 2c ). These data and the results of experiments with other promoters such as c-fes (data not shown) clearly indicate that FEV binds specifically to Ets-binding sites.
Transcriptional repression by FEV
To determine how FEV modulates Ets-dependent transcription, we studied ICAM-1-promoter-driven transcription of the luciferase reporter gene in RK-13 cells, our group having previously shown that the activity of this promoter is Ets dependent (de Launoit et al., 1998) . As shown in Figure 3a , FEV was able to inhibit the activity of wild-type human ICAM-1 promoter. Repression increased from 78 to 88% when the dose of pSV-FEV expression vector increased from 10 to 50 ng. As previously demonstrated by our group (de Launoit et al., 1998) , basal transcription decreased by more than 50% when the Ets-binding sites at positions À158 and À138 within the ICAM-1 promoter were mutated (Figure 3b ). Interestingly, FEV did not repress transcription driven by the mutated promoter ( Figure 3b ). It did reduce transcription driven by other Ets-responsive promoters. The activity of the E74 promoter (Baert et al., 2002) , for instance, was reduced by 70% in the presence of 10 ng pSV-FEV expression vector. Transcription driven by the c-fes or Neu promoter was reduced, respectively, by 21 or 37% (Figure 3a ). In parallel, we showed that Ets-independent promoters (e.g. the elongation factor 1a (EF1a) promoter -see Figure 3a ) are unaffected by similar doses of FEV. Together with similar data obtained, when the same reporter systems were used in HeLa and HEK-293 cells (not shown), these results demonstrate that FEV can act via an Ets-binding site to repress basal transcription.
We have previously shown that Ets-family transcriptional activators can increase the activity of the ICAM-1 and the c-fes promoters (de Launoit et al., 1998) . Ectopically expressed ERM and Ets-1 were shown to activate the ICAM-1 promoter (respectively 6.2-and 2.5-fold), whereas Pu-1 had no effect (Figure 4a ). Expression of FEV under these conditions (10 ng expression vector) caused ERM-and Ets-1-transactivated transcription to decrease dramatically to only 8 or 28% respectively of the level observed in the absence of FEV. This represents only 50 or 70% respectively of basal-level transcription. In the presence of ectopically overexpressed Pu-1, approximately 80% repression was observed, as in the absence of Pu-1 (not shown). As shown in Figure 4b , ectopic expression of ERM, Pu-1, or Ets-1 activated the synthetic c-Fes promoter element (respectively 38-, 12.5-, or 7-fold). This transcriptional activation was decreased in a dose-dependent manner by FEV. Repression of ERM-transactivated transcription reached 85% in the presence of 10 ng pSV-FEV and 96% in the presence of 50 ng expression vector. The level of transcription in the latter case was the same as in the absence of ectopic ERM expression. The same amount of pSV-FEV vector in the presence of ectopically expressed Pu-1 or Ets-1 caused 69 or 91% repression, respectively. This decrease in transcriptional activation was not because of a decrease in the amount of ectopically expressed Ets transactivators in the presence of FEV, as demonstrated by Western blotting for Pu-1 (Figure 4c ). Hence, ectopically expressed FEV can repress transcription activated by Ets transactivators such as ERM, PEA3 (not shown), Ets-1, Ets-2 (not shown), or Pu-1.
Mapping of the FEV domains responsible for transcriptional repression
To identify the FEV regions involved in transcriptional repression, we created deletion mutants lacking parts of this repressor ( Figure 5a ) and tested them in RK-13 cells on the ICAM-1 and c-fes promoter systems. As a control, we expressed the full-length FEV 1-238 protein, showing that it dramatically repressed basal ICAM-1-promoter-driven transcription in a dose-dependent manner. Repression reached 87% in the presence of 50 ng pSG5-FEV (Figure 5b ). The N-terminally truncated FEV 43-238 protein containing both the ETS domain and the alanine-rich C-terminal domain had the same effect as full-length FEV 1-238 . In contrast, both the Cterminally truncated FEV 1-128 protein and the FEV 43-128 protein corresponding to the ETS domain repressed basal ICAM-1-promoter-driven transcription can repress transactivation by ectopically expressed Ets-family activators. RK-13 cells were transiently transfected with 50 ng of (a) ICAM WT -Luc (ICAM-1), or (b) pBfes-Luc (c-fes), reporter plasmid in a total of 300-500 ng plasmid DNA containing 20 ng pSG5-Ets1, pSG5-Pu-1, or pSG5-ERM, increasing amounts (5, 10, and 25 ng) of pSV-FEV vector, and 50 ng pEFIN-bGAL vector. The data (means7s.e.m.) were collected as in Figure 3 and are presented as fold activation relative to basal conditions without the pSG5 activator plasmid or pSV-FEV expression plasmid. (c) Ectopic fev expression did not regulate ectopic Pu-1 expression. Protein extracts were prepared from RK-13 cells transfected with a total of 400 ng DNA plasmid containing 50 ng pBfes-Luc reporter vector, 0 or 20 ng pSG5-Pu-1 expression vector, and the indicated amount of pSV-FEV expression vector. Cell extracts were separated by SDS-PAGE and electroblotted onto a nitrocellulose membrane. Western blot analyses were performed using either a specific anti-HA antibody to detect FEV or a specific anti-Pu-1 antibody to detect Pu-1 FEV is a transcriptional repressor P Maurer et al by only about 20%, whatever the dose of expression vector used ( Figure 5b ). As illustrated in Figure 5c , the results were similar with the c-fes promoter: FEV 1-238 and FEV 43-238 respectively caused 78 and 56% transcriptional repression in the presence of 50 ng expression vector, and repression was dose dependent. In contrast, the truncated FEV 1-128 and FEV 43-128 proteins had no effect. Western blotting experiments (see below) showed that the observed differences in repression were not because of differences in FEV protein production. Moreover, none of the deletions affected the nuclear localization of the resulting proteins (data not shown). These data suggest that the carboxy-terminal domain of FEV plays a critical role in repression.
We also tested the effect of these deletion mutants on ICAM-1-promoter-driven transcription, transactivated by ectopically expressed ERM. As illustrated in Figure 5d , both FEV 1-238 and FEV caused this transcription to decrease in a dose-dependent manner. When the dose of expression vector was 20 ng or more, the transcription level fell below the basal level ( ¼ 0% transactivation). Surprisingly, the truncated FEV 1-128 and FEV proteins were also able to repress transactivation by ERM in a dose-dependent manner, albeit less so than the proteins containing the carboxyterminal domain. Even high doses of the FEV 1-128 -and FEV 43-128 -expressing vectors failed to reduce transcription to a level below the basal level. As illustrated in Figure 5d , the effects observed were not because of differences in FEV mutant synthesis. Altogether, these data clearly indicate that the ETS domain of FEV can repress transcription in the absence of the carboxyterminal domain.
As removal of the alanine-rich domain might affect the protein's DNA-binding capacity, we compared the ability of full-length FEV (FEV 1-238 ) and truncated FEV 1-128 (lacking the carboxy-terminal region) to bind to a specific DNA probe. For this purpose, the FEV deletion mutants were synthesized in rabbit reticulocyte lysates and tested in EMSAs. Care was taken to use similar amounts of in vitro synthesized proteins, as judged by Western blot analysis. Figure 5e shows that in vitro synthesized FEV 1-238 bound to the Ets-binding site of the ICAM-1 promoter with a lower affinity than FEV 1-128 , which bound to the probe very strongly. The FEV protein (corresponding to the ETS domain) also displayed strong binding, whereas the aminoterminally truncated protein FEV 43-238 behaved like the full-length protein (Figure 5e ). These results strongly suggest that the carboxy-terminal domain of FEV inhibits binding of the protein to DNA. Since removal of this domain decreases transcriptional repression, while increasing specific DNA binding, it would seem that full-length FEV and FEV 43-238 repress transcription in a different manner from the FEV proteins lacking the alanine-rich domain. Strong binding to Etsbinding sites probably reinforces a passive repression mechanism. This hypothesis is supported by the fact that FEV show a similar ability to repress transcription driven by the ICAM-1 and c-fes promoters (Figures 5b and c) .
FEV represses transcription in an Ets-independent manner
To test whether FEV can repress transcription in an Etsindependent manner, we fused the full-length protein and deletion mutants to a heterologous DNA-binding domain (of the bacterial protein LEXA) and tested the ability of these fusion proteins to regulate transcription of a luciferase reporter construct driven by a promoter containing LEXA-binding sites (Figure 6a ). To permit transcriptional repression, we used an activated LEXA reporter system which, in addition to eight LEXA binding sites, contains five binding sites for the GAL4 DNA-binding domain (Lemercier et al., 2000) ( Figure 6a) . Thus, when the transcriptional activation domain of ERM (ERMa) fused to the DNA-binding domain of GAL4 (Defossez et al., 1997 ) is expressed, it can activate basal transcription by approximately 5000-fold. In this context, the LEXA-FEV 1-238 fusion protein repressed transcription by about 60% (Figure 6b ). Neither the amino-terminal domain (LEXA-FEV 1-43 ) nor the ETS domain (LEXA-FEV 43-128 ) significantly repressed transcription. In contrast, the carboxy-terminal alanine-rich domain (LEXA-FEV 129-238 ) repressed transcription dramatically, by more than 70% (Figure 6b ). This repression is not specific to the cell line used, since we obtained similar data with U2OS cells (data not shown). These data reinforce the hypothesis that FEV represses transcription by at least one active mechanism, that is, via the alanine-rich domain, this mechanism being unrelated to its ability to bind Etsbinding sites. To determine whether recruitment of HDAC activity is involved in this mechanism as it is for other repressors, we tested the effect of the specific HDAC inhibitor trichostatin A (TSA) on FEV repression. Although TSA treatment did significantly increase basal transcription (eightfold), it did not decrease FEVmediated repression in either the LEXA system (Figure 6c ) or the Ets-dependent system (not shown). Whether 200 nm TSA was present or not (Figure 6c ), the repression level observed with the LEXA-FEV 1-238 fusion protein was about the same (respectively 60 and 70%). Similar data were obtained with 50 and 1000 nm TSA and with sodium butyrate (data not shown). This result indicates that FEV represses transcription by a mechanism that does not require HDAC activity.
Effect of FEV overexpression on cells
To study the effect of long-term ectopic expression of the fev gene, we tried to produce clones stably expressing it. Of the many human cell lines tested, only HEK-293 cells yielded FEV-positive clones, and very few of them (data not shown). Likewise, RK-13 rabbit cells cotransfected with the pSG5-FEV 1-238 expression vector and a vector expressing the neomycin resistance gene yielded very few clones in the presence of neomycin (Figure 7 , compare control and FEV 1-238 ). These clones did not result from nonexpression of the fev gene, since the protein was detected by Western blotting (data not shown). Our previous experiments having shown that carboxy-and amino-terminally truncated FEV proteins repress transcription by different mechanisms, we tested the ability of cells transfected with the corresponding constructs to yield clones. As shown in Figure 7 , very few clones were obtained when RK-13 cells were transfected with the construct encoding the aminoterminally truncated FEV protein ). In contrast, long-term ectopic expression of the carboxyterminally truncated FEV protein (FEV 1-128 ) did not prevent the development of cell clones. This confirms that the two truncated FEV proteins repress transcription differently, and that the carboxy-terminal alaninerich domain is important for FEV activity.
Discussion
In the present paper, we show that the fev gene is expressed in a very restricted range of established cell lines. Among the lines tested here, the Dami megakaryocytic cell line was the only one in which we detected the presence of FEV mRNA by RT-PCR. This line also expresses other Ets-family members, such as ERM and ER81 (Monte et al., 1994 (Monte et al., , 1995 . Using the highly sensitive RT-PCR method, we were also able to detect a specific signal in human prostate cells. This is in good agreement with previous Northern blot analyses showing that fev is expressed in this organ (Peter et al., 1997) . RNase protection assays have likewise shown that the rat fev homolog pet-1 is expressed in the rat prostate (Fyodorov et al., 1998) . Rat and mouse fev/pet-1 genes have been studied in the brain. Their expression is highly specific to central neurons, colocalizing with that of the serotonin transporter gene from E11 to adulthood (Hendricks et al., 1999; Pfaar et al., 2002) . Although no other data are available on fev expression in the brain, the fact that it occurs early in mouse development suggests that it could be crucial.
Many Ets-family proteins have been shown to be targeted to the nucleus. In the present work, we likewise show that FEV ectopically overexpressed in COS-7 cells localizes exclusively to the nucleus. This is in good agreement with recent data on the nuclear localization of the murine Pet-1 in transfected HEK-293 cells. Since the nuclear localization signal of Ets proteins is generally situated in the ETS domain (Janknecht, 1996; Janknecht et al., 1996) , we have also performed experiments with FEV deletion mutants, confirming that at least one nuclear localization signal is present in this domain (data not shown).
Here we show that FEV can bind specifically to various Ets-binding sites such as those of the c-fes (data not shown) and human ICAM-1 promoters. We have previously shown that members of the Ets family regulate the ICAM-1 promoter (de Launoit et al., 1998) . Owing to this, most of the data presented here were first obtained with the human ICAM-1 promoter. We later focused on other promoters as well. In keeping with data showing that rat Pet-1 regulates transcription (Fyodorov et al., 1998) , we show here that FEV dramatically represses both basal and ectopically Etsactivated transcription driven by the ICAM-1 promoter, and that the effect is dose dependent. FEV also represses transcription driven by other Ets-responsive promoters, such as the E74, c-fes, and neu promoters. Although rat Pet-1 has additionally been shown to activate transcription driven by a specific promoter, our data on FEV are in good agreement with those showing that rat Pet-1 represses reporter-gene transcription from a plasmid containing three upstream Ets-binding sites. Yet it is not advisable to extrapolate to human FEV the transcription data obtained with rat Pet-1, because there is a major difference between the two proteins. Human FEV contains 238 residues displaying 96% sequence similarity to the predicted murine Pet-1 protein (237 residues) (Pfaar et al., 2002) , but the homologous rat Pet-1 protein includes an additional 103-residue N-terminal domain among its 340 residues (Fyodorov et al., 1998) . In the present study, we have examined the action of FEV on Ets-responsive promoters with and without ectopic Ets activation. We have demonstrated drastic transcriptional repression in both cases.
Of the approximately 30 Ets proteins currently characterized in mammals, only Net (Net, Net-b, Netc), Erf, and Tel (Tel and Tel-2) have been identified as transcriptional repressors (Mavrothalassitis and Ghysdael, 2000) . Although Net appears to repress transcription specifically through its action on the SRF/SRE ternary complex (Ducret et al., 2000) , Tel acts directly (Lopez et al., 1999) . Tel represses basal transcription of the E74 3 -tk 80 -Luc reporter plasmid (Lopez et al., 1999) , which is similar to the reporter plasmids used here. Although different cell lines were used to study Tel and FEV, similar repression levels were observed. The ability of Tel to repress transcription depends mainly on its ability to self-associate via oligomerization domains (Lopez et al., 1999) . Mapping of the functional domains of Tel has revealed that its central domain is responsible for transcriptional repression. Two domains of Net Figure 7 Long-term ectopic overexpression of FEV. RK-13 rabbit kidney cells were transfected with 930 ng pSG5 (control) or pSG5-FEV deletion vector in the presence of 70 ng pEFIN3 neomycin resistance vector. After 15 days of treatment with 800 mg/ml G418, the cells were colored with Giemsa in order to detect transformant clones FEV is a transcriptional repressor P Maurer et al likewise show transcription-suppressing ability (CriquiFilipe et al., 1999) . Our present data on FEV deletion mutants prove the presence of at least one domain involved in active repression. This domain is the carboxy-terminal part of the protein, characterized by its high alanine content. Using the heterologous LEXA system, we have confirmed the importance of this alanine-rich carboxy-terminal domain: it represses transcription as effectively as full-length FEV. Several repressors appear to possess an alanine-rich repression domain (for reviews, see Hanna-Rose and Hansen, 1996; Goodman et al., 1997) . This is the case, for example, of the TBP-binding protein Drl (Yeung et al., 1994) and of the homeodomain protein EVX1, whose repressor activity maps to a region of about 50 residues rich in alanine and proline (Briata et al., 1997) . To date, however, nobody has correlated the presence of an alanine-rich domain within a transcriptional repressor with a specific repression mechanism. Most of the domains previously characterized as repression domains recruit conventional HDACs or corepressors that are inhibited by TSA. FEV-mediated repression, on the other hand, appears to be TSA independent, since this drug failed to inhibit this repression in both the Ets-dependent and LEXA systems. This distinguishes FEV from other Ets proteins containing repressor domains different from the ETS domain. For instance, the repressive activity of Tel (which interacts with mSin3A, N-CoR, and SMRT) is strongly inhibited by TSA (Chakrabarti and Nucifora, 1999; Fenrick et al., 1999; Guidez et al., 2000) . Similarly, Net interacts with CtBP via the CID domain and uses deacetylase activity for repression (Criqui-Filipe et al., 1999) . The mechanism of action of the FEV repressor domain remains to be determined. We cannot exclude a mechanism involving contact between FEV and components of the general transcription machinery. The fact that FEV exhibit strictly the same behavior, in both transiently transfected cells (ICAM-1-promoter-driven transcription) and stably transfected ones, indicates that repression does not require the amino-terminal domain. In contrast, neither the FEV 1-128 protein nor the ETS domain alone has the same repressive effect as the full-length protein. Nor do these truncated proteins prevent stably transfected cells from growing. These observations imply a critical role for the alanine-rich carboxy-terminal domain of FEV and indicate that this transcriptional repressor plays a crucial role in cell mechanisms that remain to be identified, probably by searching for specific FEV target genes.
Materials and methods
Cell lines and prostate tissue
RK-13 rabbit kidney cells, HEK-293 human embryonic kidney cells, COS-7 monkey kidney cells, LnCaP, Du-145 and PC3 human prostatic cancer cells, and HCT-15 and Lovo human intestinal cancer cells were purchased from ATCC, and maintained at 371C in a humidified atmosphere of 5% CO 2 in Dulbecco medium supplemented with 10% fetal calf serum (Gibco). Human Dami megakaryocytic cells were cultured in Hiscove medium supplemented with 10% equine serum. The normal human prostate was obtained by surgical resection and kindly provided by Dr David Waltregny (Universite´de Lie`ge, Belgium).
Expression and reporter vectors
The human FEV cDNA (nucleotides 1-1901) subcloned in the pBSK þ vector (Peter et al., 1997) was kindly provided by Dr O Delattre (Institut Curie, Paris, France). Full-length FEV and the truncated FEV proteins were generated from constructs produced by PCR with the upstream oligonucleotides 5 0 -GAATTCGCGATGAGACAGAGCGGC-3 0 (full-length FEV and FEV 1-128 ) and 5 0 -GAATTCGGCAGCGGACAGATC-CAGCTG-3 0 (FEV ) (for the pSG5-FEV constructs, the 5 0 -GAATTC-ATGGGCAGCGGACAGATCCAGCTG-3 0 oligonucleotide was used) and with downstream oligonucleotides including the original stop codon for full-length FEV and FEV 43-238 (5 0 -GGATCCCGTCTAGTGGTAATGGCC-3 0 ) or an artificially designed stop codon for FEV (5 0 GGATCCCTAGAAGTCGAAGCGGTAGGCGTAGCG-3 0 ). All PCR products were cloned into the pCRII vector, entirely sequenced, and then cloned into the pSV vector (Laget et al., 1996) using the EcoRI and BamHI restriction sites introduced into the PCR primers. The PCR products were also cloned into the pSG5 (Promega). To obtain plasmids expressing LEXA-fused proteins, PCR fragments of FEV were generated. The FEV 1-238 FEV 43-128 fragments were the same as those used for the corresponding pSG5 constructs. The FEV 1-43 fragment was generated with the upstream oligonucleotide 5 0 -GAATTCGCGATGAGACAGAGCGGC-3 0 and the downstream oligonucleotide 5 0 -GAATTCT-TAGCCTTTCTGAACCGCGGG-3 0 . The FEV 129-238 fragment was generated with the upstream oligonucleotide 5 0 -GAATTCCAGGGCCTGGCGCAGGCC-3 0 and the downstream oligonucleotide 5 0 -GGATCCCGTCTAGTGG-TAATGGCC-3 0 . These fragments of FEV were subcloned into the pCRII vector and then inserted into the pLEXA (Clontech) vector using EcoRI/BamHI digestion (pLEXA-FEV 1-238 , pLEXA-FEV , and pLEXA-FEV 129-238 ) or EcoRI digestion (pLEXA-FEV 1-43 ). LEXA-FEV fragments were then inserted into the pcDNA3 expression vector using HindIII/BamHI digestion so as to generate the following plasmids: pcDNA3-LEXA-FEV 1-238 pcDNA3-LEXA-FEV 1-43 pcDNA3-LEXA-FEV , and pcDNA3-LEXA-FEV 129-238 allowing synthesis of chimeric proteins, each consisting of the indicated FEV protein fused to the 202 residues of the LEXA DNA-binding domain. The pGAP-ERMa vector expressing the 147 residues of the GAL4 DNA-binding domain fused to the transcriptional domain of ERM (72 first residues) has been described previously (Defossez et al., 1997) . As luciferase reporter plasmids, we used the L8G5-Luc vector kindly provided by Dr S Khochbin (Universite´de Grenoble, France) (Lemercier et al., 2000) , the pBfes-Luc vector containing three copies of the 40-mer oligonucleotide corresponding to the Ets-responsive element of the c-fes promoter (RayGallet et al., 1995) , the 3 Â E74-tk-Luc vector (Baert et al., 2002) , p756-Neu-Luc, and also ICAM WT -Luc and ICAM MUTLuc corresponding respectively to the wild-type and mutated (at positions À158 and À138) human ICAM-1 promoter fragment (bp À44 to À178) (de Launoit et al., 1998) . The SmaI/XbaI fragment of the pGL3-basic vector corresponding to the luciferase gene was subcloned into the EcoRV/XbaI restriction sites of the pEFIN3 vector (kindly provided by Euroscreen, Belgium) to generate the pEFIN-Luc vector. The pSG5-ERM, pSG5-Ets1, and pSG5-Spi/Pu-1 expression vectors have been described previously (de Launoit et al., 1998) . The pRSV-bGal and pEFIN3-bGal vectors were used to normalize transfection. The coding sequence of FEV cDNA was subcloned into the pGEXI vector (Promega) using EcoR1 sites. This yielded the pGEX-FEV vector.
Generation of stable transfectants
Stable FEV-expressing and control RK-13-cell transfectants were generated by the PEI Exgen 500 procedure (Euromedex, France) with either the pSG5, pSG5-FEV 1-238 , pSG5-FEV 1-128 , or pSG5-FEV 43-238 vector supplemented with the pEFIN3 vector (Euroscreen, Belgium). Confluent cells (50-60%) were transfected when the total amount of DNA per 35-mm dish was 1 mg. At 1 day after transfection, the cells of the three dishes were pooled and plated in a 100-mm dish and treated with 800 mg/ml G418 (Sigma). After 15 days, living cells were colored with Giemsa.
Transactivation analyses
Cells grown in 25-or 35-mm dishes were transfected in triplicate using the PEI Exgen 500 procedure (Euromedex, France), with a total of 300-500 ng DNA including 50 ng pEFIN3-bGal or pRSV-bGAL and the indicated doses of reporter and expression vectors. Luciferase activity was determined 24 h after transfection and normalized with respect to the transfection efficiency by assaying b-galactosidase activity as previously described (Laget et al., 1996) .
RNA isolation and analysis of human tissues
About 10 6 cells were frozen in liquid nitrogen and stored at À801C. RNA extraction was carried out by means of RNazol (Cinna-Biotex) as described (Monte et al., 1994) . The RT-PCR method was used to identify FEV mRNA. In a final volume of 50 ml, the PCR mixture included 4 ml diluted RT (50 ng cDNA), 5 ml MgCl 2 (15 mm), 2.5 ml dNTP (2 mm), and 1.25 U Taq DNA polymerase with 10 pm of each pair of primers. The reaction mixtures were processed through 40 cycles and the PCR products were electrophoresed in a 1% agarose gel. The primers used were as follows: 5 0 -CGG-CGGCGATGAGACAGAGCGGCGCCTCC-3 0 and 5 0 -AC-GCGATGCAGCCGGCGTTCGCGCGGTCA-3 0 , allowing amplification of a 210-bp product spanning nucleotides 577-786 of the FEV cDNA sequence (GeneBank accession number: 8923789).
Immunofluorescence studies COS-7 cells plated on coverslip slides were transfected with the pSG5-FEV construct plasmid by means of the PEI Exgen 500 procedure. After 48 h, the cells were fixed in methanol/acetone (50/50) for 2 h at À201C and incubated for 2 h at 371C with 1 : 50 diluted anti-FEV C18 goat antibody (Santa Cruz SC-6530). This was followed by a 1-h incubation at 371C with 1 : 50 diluted fluorescein-conjugated donkey anti-goat IgG antibody (Santa Cruz SC-2024), as described (Monte et al., 1995) .
Immunoblot analysis
Cell proteins were separated overnight on SDS-polyacrylamide gels at 60 V and electroblotted onto nitrocellulose filters for 80 min at 200 mA. The blots were treated with washing solution (5% fat-free milk, 0.1% Tween 20 in phosphatebuffered saline) and incubated overnight at 41C, with either a 1 : 2500 dilution of monoclonal mouse anti-HA antibody (clone 12CA5, Roche), a 1 : 2500 dilution of polyclonal rabbit antiSpi-1/Pu-1 antibody (T-21 no. 352, Santa-Cruz), or a 1 : 5000 dilution of an ETS domain-specific rabbit antibody (kindly provided by Dr Martine Duterque). The blots were washed and incubated for 1 h at room temperature, either in a 1 : 10 000 dilution of HRP-linked goat anti-mouse immunoglobulin G (Amersham) or in a 1 : 2000 dilution of HRP-linked goat anti-rabbit immunoglobulin G (Amersham). After three washes, detection was performed with the Western Lightning Chemiluminescence Reagent Plus kit (Perkin-Elmer).
Gel retardation assays
GST-FEV protein was produced in bacteria as previously described . Bacterially produced FEV or FEV synthesized in vitro using the TNT-coupled reticulocyte lysate system (Promega) was used in gel retardation experiments with a 32 P-labeled ICAM-1 oligonucleotide (sense strand: 5 0 -GGCACCCTGTCAGTCCGGAAATAACTG-CAG-3 0 ) (de Launoit et al., 1998) in the presence of 25 mm HEPES, pH 7.9; 50 mm KCl; 5 mm MgCl2; 0.5 mm EDTA; 10% glycerol; 1 mm DTT, and 1 mg poly(dI/dC). The mixture was incubated for 1 h at room temperature and loaded onto a 7% polyacrylamide gel. In competition experiments, the reactions contained a 400-fold molar excess of unlabeled double-stranded wild-type or mutant ICAM-1 oligonucleotide or E74 oligonucleotide (sense strand: 5 0 -GAGCTGAA-TAACCGGAAGTAACTCAT-3 0 ) (Coutte et al., 1999) . DNA-protein complexes were resolved by native PAGE in 0.5 Â Tris borate-EDTA buffer for 3 h at 180 V. The gels were dried and autoradiographed at À801C.
